[Impact of Diabetes Mellitus and blood glucose levels on the results of treatment of patients with ST-elevation myocardial infarction undergoing percutaneous coronary interventions].

The aim of this study was to evaluate the impact of diabetes mellitus (DM) and glucose levels on the results of treatment of patients with ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary interventions (PCIs). Materials and methods. Data were collected from all patients (n=1280) with STEMI who were admitted to the coronary care unit and underwent PCIs from 2006 to 2015. 212 (16.6%) patients with DM were compared with 1068 (83.4%) patients without DM (non-DM group). To investigate the influence of the blood glucose levels, all patients were divided into two groups above and below the median of blood glycemia (7.52 mmol/l). Results. Thus, 634 patients with high level of blood glycemia (>7.52 mmol/l) were compared with 635 patients with low level of blood glycemia (<= 7.52 mmol/l). In comparing of DM and non-DM groups there were no differences in the rate of death (5.2% vs 4.2%, p=0.526), stent thrombosis (1.4% vs 1.0%, p=0.622), recurrent myocardial infarction (MI) (1.4% vs 1.2%, p=0.813) and major adverse cardiac events (MACE) (7.5% vs 5.4%, p=0.228), which included in-hospital death, recurrent MI and stent thrombosis. The rates of angiographic success (92.9% vs 93.8%, p=0.625) and no-reflow (6.6% vs 5%, p=0.327) also were comparable between groups. The rates of death (6.3% vs 2.5%, p=0.001), MACEs (7.6% vs 4.1%, p=0.008), and no-reflow (6.9% vs 3.6%, p=0,009) were significantly higher in patients with high level of blood glycemia (>7.52 mmol/l). Angiographic success rate (95.1% vs 92.1%, p=0.029) was higher in patients with low level of glycemia (<= 7.52 mmol/l). After multivariate adjustment, high level of blood glycemia (>7.52 mmol/l) remained an independent predictor of death (OR=2.28; 95% CI 1.18-4.40, p=0.014), MACE (OR=2.08; 95% CI 1.16-3.75, p=0.014) and no-reflow (OR=2.07; 95% CI 1.15-3.74, p=0.015). At the same time DM wasn't associated with death, MACE or no-reflow. Conclusion. High level of blood glycemia was an independent predictor of death, MACE and no-reflow in patients with STEMI, undergoing PCI. The presence of DM was not associated with worse in-hospital outcomes.